GLP-1 weight-loss medications are changing how people eat, and Lumina Intelligence recently argued (for good reason) that this might be the most transformational shift that we’ll see in our lifetime when it comes to the food and drink industry.

Overview

We were in for a treat as Lumina’s presentation covered four vital topics that the industry has been digesting for a while. Those being:

  • Why the industry has had it “easy”: a growing population, more calories available per person and rising spend
  • A glimpse of the future: what’s happening in the US, where obesity rates have started to fall
  • The scale of GLP-1 use in the UK
  • How GLP-1 users spend and eat out, and what that means for menus and marketing

Key takeaways

1. Volume-led growth is over

For decades, the UK food and drink market grew on volume and as the population increased, so too did our spend on food and drink. However, while daily calories available per person sit at roughly 3,500 (Defra data), the desire to meet this figure has decreased with the introduction of GLP-1 treatments.

2. The US shows where we’re heading

Obesity rates in America have started to fall over the last three years, contrasting the 20 years prior where there had been a steady rise. The arrival of weekly GLP-1 treatments, such as Wegovy and Mounjaro, is likely the cause for such a dramatic drop – one that would have seemed impossible a few years ago.

3. This is not a niche audience

In the UK, 6.2% of people currently take a form of GLP-1, 5.8% used to and 15.1% are considering it. That’s a total of 27% of the population, or 18.4 million people. Put into perspective, that’s the same as the UK’s Netflix subscriber base.

4. Spending is mixed, but there is still real opportunity

Around half of GLP-1 users are now spending less on food and drink, across both dining in and delivery. The other half spend either the same or more, meanwhile, a fifth of this category are spending more than they used to. Where spend rises, it tends to go toward higher-quality, more nutritious or functional products. Less volume doesn’t have to mean less value.

5. Eating-out occasions are holding up

Traditional weight-loss methods such as dieting relied on willpower, which often meant avoiding social situations. GLP-1s change behaviour without that effort, as cravings feel more under-control. Users can still join friends at food-led events, but they may just order a drink – and won’t struggle to say no to the tempting dishes on offer. Drinks-only occasions have grown significantly, so expanding and diversifying your cocktails/mocktails range is a rising opportunity.

6. The question has changed

It’s no longer “will GLP-1s affect us?” but “what can we do now, ahead of our competitors?”. Menus, portion sizes, pricing, labelling and marketing all need rethinking.

What this means for your brand

GLP-1 users are a large, active and fast-growing group, and with oral GLP1 medication now available, one that is only likely to continue to increase. Brands that adapt early will have the advantage. If you’d like to talk through what this could mean for your menu or marketing, get in touch with the team at jellybean here. Equally, if you are interested in what other factors will be shaping menus in 2027 you can request our free taster of our ‘7 Trends Shaping 2027 Menus’ here.

Courtney Rodrigues